



A monthly report summarizing the Life Science transactions and trends in Washington State.

Washington State Transactions by Industry



*As of January 31st

Deals by Sector



Highlights

- *Juno Therapeutics* reached an agreement to be acquired by *Celgene* for \$9.616 billion. The acquisition builds on Celgene's shared vision to discover and develop transformative medicines for patients with incurable blood cancers.
- *Seattle Genetics, Inc.* and *Cascadian Therapeutics, Inc.* announced the signing of a definitive merger agreement under which Seattle Genetics agreed to acquire Cascadian Therapeutics. Under the terms of the agreement, Seattle Genetics will pay approximately \$614 million.
- *Adaptive Biotechnologies* received an undisclosed amount of financing from *Microsoft* by entering in a partnership to map the genetics of the human immune system, or immunome, in order to detect cancers and other diseases in their earliest stage, when they can be more effectively treated.

This report is prepared by Christina Cantillo. Questions or comments? Contact christina@lswinstitute.org.

**The data in this report are compiled from publicly disclosed information and is not independently verified by Life Science Washington.

Washington Life Science Transactions 2018

Date	Company	Type	Amount
01/02/18	Kitotech Medical	Equity	\$339,000
01/03/18	Growlife, Inc.	Debt	\$1,105,000
01/03/18	WiseRG	Equity	\$19,200,000
01/03/18	AgEnergy Solutions, LLC	Debt	\$1,750,000
01/04/18	Adaptive Biotechnologies	Corporate	undisclosed
01/05/18	Vivo-TIL Therapeutics	Equity	\$990,000
01/05/18	Harvest Direct Enterprises	Equity	\$132,500
01/05/18	Joylux, Inc.	Equity	\$5,000,000
01/08/18	Silverback Therapeutics	Other	\$3,749
01/08/18	Stratos Genomics, Inc.	Equity	\$20,156,456
01/09/18	ST Phi Therapeutics	Equity	\$500,000
01/10/18	Kv1.3 Therapeutics, Inc.	Debt	\$168,182
01/11/18	Stemgenics, Inc.	Equity	\$1,800,000
01/17/18	Immusoft	Equity	\$3,613,029
01/22/18	Juno Therapeutics, Inc./Celgene	Merger/ Acquisition	\$9,616,000,000
01/26/18	Alder Biopharmaceuticals	Equity	\$99,999,952
01/29/18	PreViser	Equity	\$3,000,000
01/31/18	Seattle Genetics/Cascadian Therapeutics	Merger/ Acquisition	\$614,000,000
2018 Total			\$10,387,757,868